Search - tctmd.com

Displaying 941 - 960 of 1139

Sort: Relevancy | Date

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Daily News

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

Michael O'Riordan

June 14, 2017

News Daily News

Run to Your Heart’s Content: Marathons Not Linked With Subclinical Atherosclerosis

Michael O'Riordan

June 09, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Daily News

Lowering of Systolic BP Beyond Current Targets Gets Boost in New Analysis

Michael O'Riordan

May 31, 2017

News Daily News

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Michael O'Riordan

May 30, 2017

News Daily News

Statins Provide No Benefit in Older Adults Without CVD: ALLHAT Analysis

Michael O'Riordan

May 29, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Michael O'Riordan

May 10, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

Advertisement

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

Run to Your Heart’s Content: Marathons Not Linked With Subclinical Atherosclerosis

Growing Gap in CVD Risk Factor Control Between Rich and Poor

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Lowering of Systolic BP Beyond Current Targets Gets Boost in New Analysis

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Statins Provide No Benefit in Older Adults Without CVD: ALLHAT Analysis

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content